Description
Recombinant Human PD-L1/B7-H1/CD274 Protein (ECD, Fc Tag)(Active) | PKSH030444 | Gentaur US, UK & Europe Disrtribition
Synonyms: Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 ligand 1; Programmed death ligand 1; B7 homolog 1; B7-H1; CD274; B7H1; PDCD1L1; PDCD1LG1; PDL1
Active Protein: Active protein
Activity: A DNA sequence encoding the human CD274 (NP_054862.1) (Met1-Thr239) was expressed with the Fc region of mouse IgG1 at the C-terminus.
Protein Construction: A DNA sequence encoding the human CD274 (NP_054862.1) (Met1-Thr239) was expressed with the Fc region of mouse IgG1 at the C-terminus.
Fusion Tag: C-Fc
Species: Human
Expressed Host: HEK293 Cells
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per µg as determined by the LAL method.
Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Molecular Mass: 51.7 kDa
Formulation: Lyophilized from sterile PBS, pH 7.4
Reconstitution: Please refer to the printed manual for detailed information.
Background: Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Immune CheckpointImmune Checkpoint Blockade: Blocking Antibodies Immune Checkpoint Blockade: PD-L1 / B7-H1 / CD274 Blocking AntibodiesImmune Checkpoint Detection: Antibodies Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IHC Antibodies Immune Checkpoint Detection: ICC Antibodies Immune Checkpoint Detection: FCM Antibodies Immune Checkpoint Detection: WB AntibodiesImmune Checkpoint Proteins PD-L1 / B7-H1 / CD274 Immune Checkpoint ProteinsImmune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy
Research Area: Cancer, immunology
